Biocon Ltd 2014 AR2
The report highlights Biocon's operational and financial performance for the fiscal year 2013-2014, emphasizing its commitment to affordable innovation in healthcare. Key achievements include the launch of ALZUMAb™, a novel anti-CD6 monoclonal antibody for psoriasis, and CANMAb™, the world's most affordable trastuzumab for breast cancer. The company also established the Biocon Academy to address the skill deficit in the biotechnology sector. On the environmental front, Biocon maintained its energy consumption at the previous year's levels despite a 16% revenue growth and continued its zero liquid discharge initiatives.
Company: Biocon Ltd
Sector: Manufacturing
Country: India
Year: 2014
Type: AR2
Pages: 196
Back to company
Biocon Ltd
Annual Report
The report highlights Biocon's operational and financial performance for the fiscal year 2013-2014, emphasizing its commitment to affordable innovation in healthcare. Key achievements include the launch of ALZUMAb™, a novel anti-CD6 monoclonal antibody for psoriasis, and CANMAb™, the world's most affordable trastuzumab for breast cancer. The company also established the Biocon Academy to address the skill deficit in the biotechnology sector. On the environmental front, Biocon maintained its energy consumption at the previous year's levels despite a 16% revenue growth and continued its zero liquid discharge initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Apr 1, 2013 - Mar 31, 2014
Fiscal Year
2014
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Workplace Fatalities
Employees